

## 1 SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses

2 Olha Puhach<sup>1</sup>, Mathilde Bellon<sup>1</sup>, Kenneth Adea<sup>1</sup>, Meriem Bekliz<sup>1</sup>, Krisztina Hosszu-Fellous<sup>2,3</sup>, Pascale  
3 Sattonnet<sup>1</sup>, Sophie Coudurier-Boeuf<sup>2,3</sup>, Isabelle Arm-Vernez<sup>2,3</sup>, Laurent Kaiser<sup>2,3</sup>, Isabella Eckerle<sup>1,2</sup>,  
4 Benjamin Meyer<sup>4</sup>

5 Affiliations:

6 <sup>1</sup>Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva,  
7 Switzerland

8 <sup>2</sup>Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland

9 <sup>3</sup>Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland

10 <sup>4</sup>Centre of Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva,  
11 Switzerland

12

13 Corresponding author:

14 Benjamin Meyer: [benjamin.meyer@unige.ch](mailto:benjamin.meyer@unige.ch)

15 Keywords: SARS-CoV-2, mucosal immunity, secretory IgA

### 16 Abstract

17 Mucosal antibodies play a key role in the protection against SARS-CoV-2 infection in the upper respiratory  
18 tract, and potentially in limiting virus replication and therefore onward transmission. While systemic  
19 immunity to SARS-CoV-2 is well understood, little is known about the antibodies present on the nasal  
20 mucosal surfaces.

21 In this study, we evaluated SARS-CoV-2 mucosal antibodies in response to infection, vaccination, or a  
22 combination of both. Paired nasal fluid and serum samples were collected from 136 individuals, which  
23 include convalescent, vaccinated, or breakthrough infections.

24 We detected a high correlation between IgG responses in serum and nasal fluids, which were higher in  
25 both compartments in vaccinated compared to convalescent participants. Contrary, nasal and systemic  
26 SARS-CoV-2 IgA responses were weakly correlated, indicating a compartmentalization between the local  
27 and systemic IgA responses. SARS-CoV-2 secretory component IgA (s-IgA) antibodies, present exclusively  
28 on mucosal surfaces, were detected in the nasal fluid only in a minority of vaccinated subjects and were  
29 significantly higher in previously infected individuals. s-IgA binding antibodies showed significant  
30 correlation with neutralizing activity of nasal fluids against SARS-CoV-2 ancestral B.1 and Omicron-BA.5  
31 variant, indicating that s-IgA is the crucial contributor to neutralization in the nasal mucosa. Neutralization  
32 against both SARS-CoV-2 strains was higher in the mucosa of subjects with previous SARS-CoV-2 infections  
33 compared to vaccinated participants.

34 In summary, we demonstrate that currently available vaccines elicit strong systemic antibody responses,  
35 but SARS-CoV-2 infection generates more potent binding and neutralizing mucosal antibodies. Our results  
36 support the importance to develop SARS-CoV-2 vaccines that elicit mucosal antibodies.

37 **One Sentence Summary:** SARS-CoV-2 infection or combination of infection and vaccination (hybrid  
38 immunity) elicit binding and functional mucosal antibody responses superior of those after systemic  
39 vaccination.

## 40 Introduction

41 Less than one year after the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-  
42 2), the causative agent of coronavirus disease 2019 (COVID-19), highly effective COVID-19 vaccines were  
43 licensed<sup>1,2</sup>. To date, more than 13 billion doses of COVID-19 vaccines have been administered worldwide,  
44 significantly reducing the number of severe diseases and hospitalizations<sup>3</sup>. However, breakthrough  
45 infections have been reported even for SARS-CoV-2 variants that are antigenically similar to the vaccine  
46 strain and more frequently since the emergence of the Omicron variant with its efficient immune evasion  
47 properties<sup>4,5</sup>. These results indicate that current vaccines can only temporarily and incompletely reduce  
48 the risk of upper respiratory tract (URT) infections<sup>6,7</sup>. In contrast, studies in mice and rhesus macaques  
49 demonstrated that intranasal immunization leads to complete protection against SARS-CoV-2 infection of  
50 the URT, resulting in reduced onward transmission<sup>8,9</sup>. In humans, the level of mucosal IgA antibodies,  
51 elicited mainly by previous SARS-CoV-2 infection, was associated with protection from infection with  
52 Omicron subvariants<sup>10</sup>. However, the origin of these mucosal IgA antibodies as well as their functional  
53 properties have not been investigated in detail.

54 The URT harbours a distinct part of the immune system called the mucosa associated lymphatic tissue  
55 (MALT), where local plasma cells secrete multimeric IgA (mainly dimers but also trimers and tetramers),  
56 which is transported across the mucosal epithelium by the polymeric immunoglobulin receptor (pIgR).  
57 During this process the extracellular part of the pIgR, called the secretory component (SC) is bound to the  
58 multimeric IgA forming secretory IgA (s-IgA). The main function of s-IgA antibodies is neutralization<sup>11</sup>. In  
59 particular, s-IgA dimers were shown to neutralize SARS-CoV-2 on average 15 times more potently than  
60 IgA monomers present in serum<sup>12</sup>. Mucosal IgG is either locally produced by B cells in the lamina propria  
61 and transported across the epithelium by neonatal Fc receptors, or excreted as a transudate from serum  
62 together with monomeric IgA antibodies<sup>13</sup>. While potent systemic IgA and IgG responses are shown to be  
63 induced by infection and vaccination, mucosal antibody responses are mainly induced by infection<sup>14</sup>.  
64 Notably, some studies demonstrated that virus-specific mucosal IgA antibodies were found in some  
65 seronegative COVID-19 patients, suggesting a discrepancy between local and systemic antibody immune  
66 responses<sup>15,16</sup>. In convalescent patients higher SARS-CoV-2-specific mucosal antibodies were associated  
67 with lower viral loads and more efficient symptom resolution<sup>17</sup>; these antibody responses remained  
68 detectable for at least 3 months post infection in saliva<sup>18</sup>, and up to 9 month post infection in nasal  
69 secretions<sup>17,19</sup>.

70 Vaccination was shown to significantly reduce infectious viral loads in breakthrough infections with the  
71 Alpha variant, but the effect was weaker for breakthrough infections with Delta<sup>20,21</sup>, and even less potent  
72 for the Omicron BA.1 variant, where the decrease of viral loads was shown only after boosting with a 3<sup>rd</sup>  
73 vaccine dose<sup>22,23</sup>. However, it remains unclear whether this reduction is caused by mucosal or systemic  
74 immunity. Even though s-IgA responses were detectable in saliva of some of the vaccinated subjects<sup>24</sup>,  
75 these responses were significantly lower in comparison to previously infected individuals<sup>25,26</sup>. Additionally,

76 most virus-specific antibody titers in saliva and their neutralizing capacity significantly decayed six months  
77 post vaccination<sup>25</sup>. One study showed that mucosal antibody responses induced by vaccination were low  
78 or undetectable, but Delta breakthrough infections led to significant increases of antibody titres in saliva<sup>27</sup>.  
79 According to one study, previous infection, but not vaccination, induced strong IgA responses and  
80 detectable neutralizing titers against Omicron subvariants in the nasal mucosa<sup>28</sup>.

81 In this study we characterized mucosal antibody responses in the URT of convalescent, vaccinated and  
82 subjects with vaccine breakthrough infections. We quantified and compared the levels of mucosal and  
83 systemic IgA and IgG responses in these groups as well as analyzed the levels of neutralizing antibodies in  
84 the nasal lining fluid (NLF).

## 85 **Materials and methods**

### 86 **Study design and participants**

87 The study was approved by the Cantonal Ethics Committee at the University Hospital of Geneva (CCER no.  
88 2020-02323). All study participants provided written informed consent. NLF and serum samples were  
89 collected during a single visit from all the participants from September 2021 to June 2022. The samples  
90 were collected from healthy volunteers with no symptoms of respiratory illness. All the sampling  
91 procedures were performed by trained healthcare professionals. The information about previous  
92 infections (date of infection confirmed by RT-PCR or rapid antigenic test) and vaccination (date of  
93 vaccination, number of vaccine doses and the vaccine manufacturer) was collected using a questionnaire  
94 during the visit.

95 NLF samples were collected using the Nasosorption™ FX-i nasal sampling device (Hunt Developments, UK)  
96 as previously described<sup>29</sup>. Briefly, a synthetic absorptive matrix (SAM) strip was inserted in the nostril of  
97 the participant against the inferior turbinate. After pressing on the side of the nostril for one minute, the  
98 SAM strip was removed and placed in the collection tube. The samples were stored at -80°C before  
99 processing. Nasosorption devices were thawed on ice, the SAM was removed and placed in the collection  
100 tube with 300 µl of elution buffer (PBS/1% BSA). Following incubation for 10 minutes at room  
101 temperature, the SAM was placed on the spin-X filter Eppendorf tube and centrifuged at 16,000 g for 10  
102 min at 4 °C. Eluted liquid was aliquoted and kept at -80 °C until further use.

### 103 **Immunoassays**

#### 104 **Roche Elecsys anti-SARS-CoV-2 S RBD and Roche Elecsys**

105 Elecsys anti-SARS-CoV-2 S and anti-SARS-CoV-2 were used to determine the levels of SARS-CoV-2 specific  
106 RBD and nucleoprotein antibodies respectively. Antibody measurements were performed on the cobas  
107 e801 analyser (Roche Diagnostics, Rotkreuz, Switzerland) in the clinical laboratory of the University  
108 Hospital of Geneva. For anti-RBD antibodies, results are reported as concentrations (U/mL) and positivity  
109 was determined by using the manufacturer's cut-off >0.8 U/mL. For anti-NP antibodies, the positivity was  
110 determined with a cut-off index (COI), where COI ≥1.0 is defined as positive.

#### 111 **Recombinant proteins**

112 Full-length trimerized SARS-CoV-2 spike (triS) was provided by the EPFL protein production facility.  
113 Nucleoprotein (NP) was obtained from Prospec Bio.

## 114 **Human total IgA ELISA**

115 The levels of total IgA in NLF were measured by IgA Human Uncoated ELISA Kit (Catalog # 88-50600,  
116 Invitrogen) following the manufacturer's instructions. NLF samples were diluted to 1:1000 and 1:10000 in  
117 assay buffer prior to measurement. The standard curve was generated from recombinant human IgA using  
118 four-parameter logistic (4PL) regression model. The relative IgA concentration (ng/mL) of test samples  
119 was determined according to the dynamic range of the standard curve by interpolating the concentration  
120 of the standards that correspond to the absorbance value.

121 To normalize all SARS-CoV-2 IgA levels in NLF samples to total IgA, a correction factor calculated by  
122 dividing the mean of total IgA for all samples by the sample's total IgA was applied to all the NLF samples.

## 123 **IgA and IgG Anti-SARS-CoV-2 tris ELISA**

124 Maxisorp plates (Thermo Fisher Scientific) were coated with SARS-CoV-2 full triS protein diluted in  
125 Phosphate-Buffered Saline (Thermo Fisher Scientific) at a concentration of 2 $\mu$ g/ml. 50  $\mu$ l of diluted antigen  
126 was added to each well and incubated overnight at 4°C. To control for unspecific binding half of the plate  
127 was coated with PBS only. Following three washes with washing buffer (PBS/0.1% tween-20), plates were  
128 blocked for one hour at 37°C with assay buffer (PBS/1% BSA/0.1% tween-20). Human IgA SARS-CoV-2 S  
129 monoclonal antibodies (IgA1 AR222, Geneva Antibody Facility) were serially diluted in assay buffer (3-fold  
130 serial dilutions from 300 ng/ml to 0.41 ng/ml) and added to each plate to generate a relative IgA anti-S  
131 standard curve. Human IgG SARS-CoV-2 S monoclonal antibody (IgG1 AR222, Geneva Antibody Facility)  
132 (3-fold serial dilutions from 100ng/ml to 4.6 pg/ml) was used to generate IgG anti-S standard curve. For  
133 IgA anti-SARS-CoV-2 tris ELISA, 3-fold dilutions from 1:5 to 1:45 in assay buffer prepared for NLF and 1:100,  
134 1:900, and 1:2700 dilutions in assay buffer prepared for serum samples). For IgG anti-SARS-CoV-2 tris  
135 ELISA, 9-fold dilutions were prepared for serum (1:100 to 1:24300) and 3-fold dilutions were prepared for  
136 NLF (1:15 to 1:45). 50  $\mu$ l of standard and sample dilutions in duplicates were added to coated and  
137 uncoated wells and incubated for 1 hour at 37°C. Plates were washed four times and 50  $\mu$ l of Peroxidase  
138 AffiniPure Goat Anti-Human Serum IgA (Cat. # 109-035-011, Jackson ImmunoResearch) for IgA ELISA or  
139 Peroxidase AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Human IgG (109-036-098, Jackson) antibodies for IgG  
140 ELISA at a 1:5000 dilution were added to all wells. After 1 hour of incubation at 37°C and four washes and  
141 plates were developed with 3,3',5,5'-Tetramethylbenzidine (TMB) (Sigma-Aldrich) for 20 minutes in the  
142 dark. The reactions were stopped with 1N sulfuric acid. The developed plates were read at 450 nm  
143 wavelength. The absorbance values measured from uncoated wells were subtracted from values obtained  
144 from antigen-coated wells. The SARS-CoV-2 IgA standard curve was generated from the human IgA SARS-  
145 CoV-2 S mAb using a 4PL regression model. The relative anti-S IgA concentrations (ng/mL) of test samples  
146 were determined by interpolation of optical density values on a standard curve. The mean + 3SD of eleven  
147 negative samples was used to set a cut-off for anti-SARS-CoV-2 IgA and IgG in NLF. The mean + 3SD of 56  
148 or 48 pre-pandemic samples was used to set a cut-off in serum for IgA anti-SARS-CoV-2 or IgG anti-SARS-  
149 CoV-2 respectively.

## 150 **Multiplex immunoassay**

151 For s-IgA analysis in NLF, a fluorescent-bead-based multiplex immunoassay was developed. Full-length  
152 His-tagged SARS-CoV-2 Spike and Nucleoprotein were each coupled to MagPlex carboxylated polystyrene  
153 microparticles using xMAP<sup>®</sup> Antibody Coupling Kit (Luminex) following manufacturer's instructions.

154 Antigen-conjugated microspheres were resuspended at a concentration of  $1 \times 10^4$  /ml and incubated in  
155 assay buffer (PBS/1% BSA/0.1% tween-20) for 1 hour at room temperature. A total of 4 NLF samples  
156 collected from a subject with previously confirmed SARS-CoV-2 infection were pooled together and used  
157 to create standard curves for SARS-CoV-2 triS and NP s-IgA. 3-fold serial dilutions were performed for NLF  
158 samples (1:3 to 1:81 in assay buffer). Diluted samples and standards were incubated with antigen-coupled  
159 microspheres for 2 hours while shaking at 800 rpm. Following 3 washes with PBS/0.1% BSA/0.1% tween-  
160 20, mouse anti-Human IgA secretory component antibodies (Catalog # ABIN6155159, Antibodies online)  
161 was added to microspheres and incubated for 1 hour at room temperature. Following three washes the  
162 data was acquired on Bio-Plex® MAGPIX™ Multiplex Reader. MFI was converted to arbitrary units (AU/ml)  
163 by interpolation from a log-4PL-parameter logistic standard curve (3000 AU/ml to 4.12 AU/ml). Samples  
164 with values of less than 12 AU/ml were considered negative and an arbitrary value of 6 AU/ml was  
165 assigned to these samples. The mean + 3SD of eleven negative samples was used to set a cut-off for NLF.

## 166 **Viruses and cells**

167 Vero E6-TMPRSS cells (Catalog # 100978, National Institute for Biological Standards and Controls) were  
168 cultured in complete DMEM GlutaMAX medium supplemented with 10% FBS, 1× non-essential amino  
169 acids and 1% antibiotics (penicillin–streptomycin) (all reagents from Gibco).

170 All SARS-CoV-2 viruses used in this study were isolated from residual nasopharyngeal swabs collected  
171 from patients at the University Hospital of Geneva under general informed consent that allows the usage  
172 of anonymized left-over materials. All patient specimens from which isolates were obtained were fully  
173 sequenced. The SARS-CoV-2 B.1 variant was isolated and propagated on Vero-E6 cells. The Omicron-BA.5  
174 variant was primarily isolated on Vero-TMPRSS cells, then transferred to Vero-E6 for generation of virus  
175 stock. All virus stocks were titrated on Vero E6-TMPRSS cells and fully sequenced. All infection  
176 experiments were performed under Biosafety Level 3 conditions.

## 177 **Focus Reduction Neutralization Assays**

178 Serially diluted NLF and SARS-CoV-2 (50 focus-forming units) were combined in serum-free Opti-Pro  
179 medium (Gibco) and DMEM + 1%FBS (Corning Cellgro) and incubated at 37°C for one hour. The antibody-  
180 virus mixture was added to a monolayer of Vero E6-TMPRSS cells and incubated at 37°C for one hour.  
181 After 1 hour at 37 °C, the media were removed, and pre-warmed medium mixed with 2.4% Avicel (DuPont)  
182 at a 1:1 ratio was overlaid. Plates were incubated at 37 °C for 24 hours and then fixed using 6%  
183 paraformaldehyde for 1 hour at room temperature. The staining for SARS-CoV-2 nucleocapsid protein was  
184 done as described previously<sup>22</sup>.

185 The 50% reduction endpoint titers (FRNT<sub>50</sub>) were calculated by fitting a 4-PL logistics curve with variable  
186 slope to the number of foci of each NLF using GraphPad Prism version 9.1.0. If the extrapolation reached  
187 a titer below 0.5, the value of 0.5 was attributed to the sample.

## 188 **Statistical analysis**

189 Data collection was done using Excel 2019. All statistical analyses were performed using Prism version  
190 9.3.1 (GraphPad). All IgA and IgG antibody titers were  $\log_{10}$  transformed, and samples with no detectable  
191 antibodies were set to 1 ng/ml for the purpose of analysis. Differences between antibody titers between  
192 the different groups were analyzed with one-way ANOVA with Tukey test. Correlations between antibody  
193 titers were analyzed using Pearson's rank test.

194 Abbreviations:

195 NLF – nasal lining fluid

196 triS – trimeric Spike

197 NP – Nucleoprotein

## 198 **Results**

### 199 **Study design and participants**

200 In this study we determined the quantity and quality of SARS-CoV-2-specific mucosal antibodies in  
201 individuals that have only been vaccinated or infected, or have hybrid immunity and compared them to  
202 the systemic responses. A total of 143 adults were recruited between September 2021 and June 2022.  
203 Paired nasal lining fluid (NLF) and serum samples were collected during a single visit from all study  
204 participants. 11 participants, which had not been vaccinated and never tested positive for SARS-CoV-2,  
205 served as a negative control group. 29 and 25 participants had been vaccinated with 2 or 3 doses,  
206 respectively, but never tested positive for SARS-CoV-2. 21 participants had been tested positive for SARS-  
207 CoV-2 previously, but were not vaccinated. 31 and 26 participants tested positive after having received  
208 1/2 or 3 doses of COVID-19 vaccine, respectively. All groups had a similar median age ranging between  
209 28.5 and 39 years. Percentage of female participants was slightly higher in the negative, convalescent and  
210 vaccinated (2 doses) groups. All participants reported mild to moderated disease at the time of infection.  
211 We used days since the last immune response (DLIR) either elicited by infection or vaccination to compare  
212 the different groups. Median DLIR was 68 days for convalescent, 176 and 70 days for individuals  
213 vaccinated with 2 or 3 doses, respectively, and 44 or 47.5 days for vaccine breakthrough after 1/2 or 3  
214 doses respectively (**Table 1**). Sequence information to determine the infecting variant was only available  
215 for a minority of participants. Nevertheless, in case only one variant circulated at the time of the positive  
216 test, we assumed that this variant infected the participant. If more than one variant circulated at the time,  
217 we marked the infecting variant as unknown. More details on the type of vaccinations received and the  
218 time between sampling, vaccination and infection are shown in **Table S1**.

219 To ensure that participants were assigned to the correct group, we tested serum samples for the presence  
220 of SARS-CoV-2-specific anti- nucleoprotein (NP) and receptor-binding domain (RBD) antibodies using the  
221 Roche Elecsys N and S assays. Highest anti-RBD serum responses were detected in participants vaccinated  
222 with 3 doses and with hybrid immunity, irrespective of the number of vaccine doses received. Participants  
223 vaccinated with 2 doses or convalescent individuals had lower anti-RBD titers, while no anti-RBD  
224 antibodies were detected in the negative group (**Figure S1A**). Anti-NP responses were only detected in  
225 convalescent individuals or participants with hybrid immunity, but not in negative or vaccinated  
226 participants confirming the absence of previous infection in these groups (**Figure S1B**). Therefore, we used  
227 samples from the negative cohort to determine the assay background and define the cut-offs of positivity  
228 for antibody responses in NLF. Since IgA concentrations in NLF might vary between individuals and  
229 between sampling we measured the level of total IgA. We found no significant differences of total IgA in  
230 the NLF of all groups compared to the negative control group, confirming that sampling of NLF by SAM  
231 strips leads to low sampling variability (**Figure S1C**). Nevertheless, to avoid a possible sampling bias on  
232 individual level, we used the levels of total IgA to normalize the levels of SARS-CoV-2-specific IgA and s-  
233 IgA antibodies in NLF.

## 234 **Distinct nasal and systemic IgA responses.**

235 First, we investigated whether there are differences between antibodies present at the nasal mucosa and  
236 those circulating the blood. Therefore, we measured the levels of IgA and IgG antibodies responses to  
237 trimeric spike (triS) protein of SARS-CoV-2 (strain: Wuhan-HU-1) in serum and NLF using an ELISA. We  
238 detected only a low correlation between levels of anti-triS IgA antibodies in serum and NLF (Pearson  
239  $r=0.23$ ,  $p=0.0082$ ), but a high correlation between anti-triS IgG responses in serum and NLF (Pearson  
240  $r=0.75$ ,  $p<0.0001$ ) (**Figure 1A and B**). These findings indicate that while SARS-CoV-2 IgG mucosal and  
241 systemic responses are highly comparable, there is a compartmentalization between IgA responses in  
242 mucosa and serum.

## 243 **SARS-CoV-2 mucosal antibodies in response to infection and vaccination**

244 Next, we investigated the level of mucosal antibodies induced by vaccination or infection by analyzing  
245 anti-triS IgA responses in NLF of vaccinated and convalescent subjects. In most of vaccinated subjects, NLF  
246 IgA responses were below the cut-off of positivity (21 out of 29 double-vaccinated and 15 of 25 in triple-  
247 vaccinated below the cut-off) and there was no difference if participants had received 2 or 3 doses despite  
248 the higher median DLIR in double-vaccinated individuals (176 vs 70 days). In contrast, positive IgA  
249 responses were detected in NLF of most of the convalescent individuals (16 out of 21 above cut-off), and  
250 they were significantly higher in comparison to vaccinated subjects (**Figure 2A**). Conversely, anti-triS IgA  
251 responses were moderately higher in serum of vaccinated subjects that had received 2 or 3 doses  
252 compared to the convalescent group, but the difference was not significant (**Figure 2B**).

253 To exclude that the observed differences in IgA are biased by exudate of serum IgA, we analyzed the levels  
254 of locally-produced anti-triS s-IgA in NLF. Notably, we observed a strong and significant correlation  
255 between anti-triS IgA and anti-triS s-IgA responses in NLF (Pearson  $r=0.64$ ,  $p<0.0001$ ) (**Supplementary**  
256 **figure 2**) indicating that the majority of IgA measured in NLF is locally produced s-IgA. Among most of the  
257 subjects who received two or three vaccine doses, the detected levels of Spike-specific s-IgA responses  
258 were either below the cut-off of positivity or they were very low (24 out of 29 double-vaccinated and 18  
259 of 25 in triple-vaccinated below the cut-off), whereas previous infection elicited significantly higher anti-  
260 triS s-IgA responses in comparison to vaccination (15 out of 21 above cut-off) (**Figure 2C**). Similar to anti-  
261 triS IgA responses, there also was no significant difference of anti-triS s-IgA between vaccinated subjects  
262 which received two or three vaccine doses, indicating that a 3<sup>rd</sup> vaccine dose does not boost local s-IgA  
263 responses.

264 We then analyzed the influence of vaccination and infection on mucosal and systemic IgG responses. We  
265 detected significantly higher anti-triS IgG responses in NLF of vaccinated participants compared to the  
266 convalescent group, while among vaccinated individuals higher anti-triS IgG titers were found in subjects  
267 who received 3 vaccine doses (**Figure 2D**). A similar pattern was observed in serum anti-triS IgG responses,  
268 confirming the highly similar profiles of SARS-CoV-2 IgG responses in nasal mucosa and serum (**Figure 2E**).

## 269 **Influence of hybrid immunity on mucosal antibody responses**

270 To evaluate the impact of hybrid immunity on mucosal antibody responses, we compared antibody titers  
271 between convalescent participants and vaccinated participants which were subsequently infected. We  
272 detected moderately higher anti-triS IgA responses in NLF of individuals with hybrid immunity in  
273 comparison to convalescent subjects, however these were significantly higher only in subjects that have

274 received three vaccine doses (**Figure 3A**). Serum anti-triS IgA responses were significantly higher in  
275 subjects with hybrid immunity after 1/2 or 3 doses in comparison to convalescent subjects (**Figure 3B**). To  
276 assess the influence of hybrid immunity on the locally-generated immune responses, we determined the  
277 levels of anti-triS s-IgA in these groups. Moderately elevated levels of anti-triS s-IgA were detected in  
278 individuals with hybrid immunity compared to convalescent subjects, however these were only significant  
279 in subjects that received 1/2 vaccine doses (**Figure 3C**). These results suggest that vaccination before  
280 infection has only a moderate impact on locally-generated immune responses.

281 We then evaluated the impact of hybrid immunity on local and systemic IgG responses. Anti-triS IgG  
282 responses in NLF were significantly higher in vaccine breakthroughs in comparison to convalescent  
283 participants (**Figure 3D**). Similar to NLF, anti-triS IgG serum responses were also significantly elevated in  
284 breakthroughs in comparison to convalescent participants (**Figure 3E**). These results suggest that while  
285 vaccination boosts local IgG responses, it has rather limited impact on local IgA responses.

286 We also examined if anti-NP s-IgA responses are induced by infection in NLF and compared them to anti-  
287 triS antibody titers. Remarkably, there was only weak correlation between anti-triS and anti-NP s-IgA  
288 mucosal responses in individuals with previous infection (Pearson  $r=0.19$ ;  $p=0.1$ ) (**Figure S3A**). In the  
289 majority of subjects with previous infection anti-NP s-IgA responses in NLF were below the cut-off of  
290 positivity (17 out of 21 in convalescent, 24 out of 31 in subjects with hybrid immunity after 1/2 doses and  
291 17 of 26 in subjects with hybrid immunity after 3 doses and) and there was no significant difference  
292 between convalescent subjects and vaccine breakthroughs (**Figure S3B**), suggesting that anti-NP s-IgA  
293 responses are either produced at very low levels or wane quickly.

#### 294 **Neutralization capacity of mucosal antibodies**

295 Last, we asked how efficient mucosal antibodies neutralize the ancestral SARS-CoV-2 strain and the  
296 Omicron BA.5 variant. Therefore, we performed a focus reduction neutralization test (FRNT) using NLF  
297 from participants that were only vaccinated with three vaccine doses and subjects with hybrid immunity  
298 acquired either by infection with the Delta or Omicron BA.1 variant after vaccination. Individuals with  
299 hybrid immunity had significantly higher neutralizing antibody titers against the ancestral SARS-CoV-2  
300 strain in NLF compared to vaccinated individuals independently of the infecting variant (**Figure 4A left**  
301 **panel**). Next, we wanted to assess whether individuals with Delta and Omicron BA.1 derived hybrid  
302 immunity were better protected against infection with Omicron BA.5 compared to vaccinated subjects.  
303 We observed significantly higher neutralization capacity against Omicron BA.5 in subjects that were  
304 previously infected with Omicron BA.1 (**Figure 4B, left panel**). Since neutralization is measured isotype  
305 independent in our assay, we wanted to determine the contribution of mucosal s-IgA. Therefore, we  
306 correlated neutralizing antibody titers against the ancestral strain and Omicron BA.5 with s-IgA binding  
307 antibodies directed against triS. Anti-triS s-IgA binding antibodies in NLF showed a moderate to strong  
308 correlation with neutralizing activity against both SARS-CoV-2 strains (**Figure 4A and B, right panel**). These  
309 findings indicate that s-IgA is a pivotal contributor to neutralization in the mucosa.

#### 310 **Discussion**

311 In this study, we investigated mucosal antibody responses following COVID-19 vaccination, infection with  
312 SARS-CoV-2 or infection in vaccinated individuals, i.e. hybrid immunity. We demonstrated that s-IgA  
313 antibodies, which are present only on mucosal surfaces and not in systemic circulation, are the main  
314 contributor to neutralization in the mucosa. Additionally, we have shown that s-IgA responses are



315 significantly elevated in subjects with previous infection, whereas vaccination-induced s-IgA responses  
316 are rarely detected and only at a very low level. Moreover, we found significantly higher neutralization  
317 titers against the ancestral SARS-CoV-2 strain in individuals with hybrid immunity compared to vaccinated  
318 subjects, providing evidence that previous infection elicits more potent functional mucosal antibodies.  
319 Interestingly, infection with Omicron BA.1 or Delta led to a similar neutralization capacity against Omicron  
320 BA.5 despite the smaller antigenic distance between BA.1 and BA.5, suggesting that the infecting variant  
321 is less important for protection. Contrary, in a study by Malato et al. a higher protection against BA.5  
322 infection was found in individuals previously infected with BA.1/2 compared to Delta. However, in this  
323 study the difference in protection from Omicron BA.5 infection by previous infection with BA.1/2 or Delta  
324 was small and potential increased waning of immunity in Delta infected participants due to the longer  
325 time span was not accounted for<sup>30</sup>.

326 Our results show that mucosal and systemic IgG responses are highly similar, whereas mucosal IgA  
327 responses are compartmentalized from systemic responses. This is consistent with previous studies that  
328 show the discordance of local and systemic SARS-CoV-2 antibody responses<sup>15,16,31</sup>. In convalescent  
329 subjects, neutralization activity poorly correlated between nasopharyngeal and blood samples<sup>16,31</sup>.  
330 Interestingly, potent antibody responses in nasal fluids were found in some seronegative participants<sup>15,16</sup>,  
331 indicating that in some cases SARS-CoV-2 infections lead only to a local but no systemic response.

332 We demonstrated that currently available intramuscularly-administered vaccines have a limited impact  
333 on SARS-CoV-2 specific mucosal responses. These results go in line with another study showing that  
334 vaccination efficiently boosts nasal IgG responses whereas nasal IgA responses are only transiently  
335 increased, and rapidly decline after vaccination<sup>19</sup>. In another study vaccination did not generate  
336 detectable neutralizing mucosal antibodies and only breakthrough infections in vaccinated subjects  
337 resulted in measurable neutralization<sup>28</sup>. To date, the presence of SARS-CoV-2 s-IgA responses were  
338 detected in saliva and breastmilk of some individuals upon vaccination<sup>32</sup>. However, the levels of s-IgA  
339 antibodies in most subjects, who received mRNA vaccines was very low or below the detection limit<sup>26</sup>.  
340 According to one study, anti-triS s-IgA responses were detected in saliva in 30% of subjects after two doses  
341 of mRNA vaccines, and the detected levels were significantly lower compared to convalescent patients<sup>25</sup>.  
342 It remains unknown how mucosal s-IgA responses can be induced upon intramuscular vaccination. SARS-  
343 CoV-2 spike protein was detected in plasma after mRNA vaccination, and the clearance of this antigen  
344 correlated with the production of IgA antibodies, indicating that this antigen could reach the MALT to  
345 further induce mucosal antibody responses<sup>33</sup>. Alternatively, after vaccination antigen diffuses to the  
346 regional draining lymph nodes, where it is taken up by local antigen-presenting cells, that can further  
347 migrate to the MALT and activate B cells that generate s-IgA antibodies<sup>34</sup>.

348 Here we show that s-IgA is an important contributor to neutralization in the NLF. Similarly, it has been  
349 demonstrated that IgA antibodies in nasal secretions are most strongly correlated with SARS-CoV-2  
350 neutralization<sup>35</sup>. Another study has shown that depletion of IgA from nasal wash samples lead to a  
351 reduction of the neutralization capacity<sup>31</sup>. One study demonstrated that higher levels of mucosal IgA but  
352 not IgG antibodies correlated with lower levels of viral replication and lower risk of infection with  
353 Omicron<sup>36</sup>. Furthermore, increased disease severity and mortality was identified among patients with IgA  
354 deficiency<sup>37</sup>. However, further studies which would evaluate the role of pre-existing immunity on SARS-  
355 CoV-2 shedding and infection rates are currently missing. A recent study evaluated the effect of different  
356 vaccine administration routes on viral transmission in hamsters. Intranasally-administered adenovirus-  
357 vector vaccine or infection lead to significantly lower cumulative shedding or airborne transmission in

358 comparison to intramuscular vaccine administration<sup>38</sup>. Indeed, mucosally-administered vaccines are  
359 proposed as a strategy to reduce onward transmission. In our study, we detected the most potent local  
360 and systemic antibody responses in subjects with hybrid immunity. Heterologous vaccination strategies  
361 that mimic hybrid immunity by giving a systemic prime through intramuscular vaccination followed by a  
362 mucosal boost, by intranasal vaccination, were shown to induce robust T and B cell immunity in the  
363 respiratory mucosa<sup>39,40</sup>. It is currently unknown how long mucosal antibodies titres induced by mucosal  
364 vaccination remain sufficiently elevated to protect from SARS-CoV-2 infection. A recent study  
365 demonstrated that protection mediated by mucosal IgA antibodies lasted at least for 8 months following  
366 SARS-CoV-2 infection<sup>10</sup>.

367 This study has some limitations. All participants were sampled only at a single time point, therefore we  
368 compared antibody responses between different individuals rather than following the same individuals to  
369 compare changes of antibody responses over time or after subsequent immune reactions. Moreover, the  
370 sampling time points were not identical for all the participants within each group. However, all groups  
371 have similar age and sex distribution validating our conclusions. Most of the study participants were young  
372 adults, which might present more potent immune responses in comparison to older subjects, therefore  
373 these results cannot be extrapolated across age groups. Furthermore, all of the participants received  
374 mRNA vaccines, while mucosal antibody responses to other types of COVID-19 vaccines, mainly used in  
375 the low- and middle-income countries, have not yet been investigated.

376 While serum neutralization titers are highly predictive of immune protection from COVID-19 disease,  
377 correlates of protection from infection and transmission are not well defined. In this study we have shown  
378 that prior infection leads to more robust mucosal binding and neutralizing antibody responses, with s-IgA  
379 seemingly to play a crucial role. Therefore, the development of vaccines that elicit strong and lasting  
380 mucosal antibody responses would be vital to curtail infectious shedding and further transmission.

### 381 **Acknowledgements**

382 We thank Pauline Vetter, Morgann Duverger, Rachel Goldstein and Christiane Eberhardt for their help  
383 with clinical sample collection. We thank Florence Pojer, Kelvin Lau, and David Hacker from the EPFL  
384 Protein Production Facility for providing us with the purified SARS-CoV-2 spike protein. We thank the staff  
385 of the laboratory of virology at the HUG for support. We are grateful for the patients who were willing to  
386 donate their samples and agree to participate in our research.

### 387 **Funding**

388 The work was funded by the COVID-19 National Research Program (grant number 198412) of the Swiss  
389 National Science Foundation.

### 390 **Author contributions**

391 O.P., I.E. and B.M. conceptualized the study. O.P., K.H.F., Ma.B. and Me.B. conducted the recruitment of  
392 participants. O.P., Ma.B., K.H.F. and Me.B. collected the clinical samples. O.P., K.A, Me.B. P.S., S.C.B, I.A.V  
393 performed the laboratory experiments. O.P., I.E. and B.M. analyzed and interpreted the data. I.E. and B.M.  
394 supervised the work. O.P., I.E. and B.M. wrote the manuscript. All authors contributed to the final draft.

395

396

397 **References**


- 398 1. Baden, L.R., *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **384**,  
399 403-416 (2021).
- 400 2. Polack, F.P., *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* **383**,  
401 2603-2615 (2020).
- 402 3. Feikin, D.R., *et al.* Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-  
403 19 disease: results of a systematic review and meta-regression. *Lancet* **399**, 924-944 (2022).
- 404 4. Bekliz, M., *et al.* Neutralization capacity of antibodies elicited through homologous or  
405 heterologous infection or vaccination against SARS-CoV-2 VOCs. *Nat Commun* **13**, 3840 (2022).
- 406 5. Carreño, J.M., *et al.* Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.  
407 *Nature* **602**, 682-688 (2022).
- 408 6. Powell, A.A., *et al.* Protection against symptomatic infection with delta (B.1.617.2) and omicron  
409 (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in  
410 adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-  
411 control study. *Lancet Infect Dis* (2022).
- 412 7. Nielsen, K.F., *et al.* Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha,  
413 Delta, or Omicron dominance: A Danish nationwide study. *PLoS Med* **19**, e1004037 (2022).
- 414 8. Hassan, A.O., *et al.* A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory  
415 Tracts against SARS-CoV-2. *Cell* **183**, 169-184.e113 (2020).
- 416 9. Afkhami, S., *et al.* Respiratory mucosal delivery of next-generation COVID-19 vaccine provides  
417 robust protection against both ancestral and variant strains of SARS-CoV-2. *Cell* **185**, 896-  
418 915.e819 (2022).
- 419 10. Marking, U., *et al.* 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and  
420 protection. *Lancet Infect Dis* **23**, 150-152 (2023).
- 421 11. Mostaghimi, D., Valdez, C.N., Larson, H.T., Kalinich, C.C. & Iwasaki, A. Prevention of host-to-host  
422 transmission by SARS-CoV-2 vaccines. *Lancet Infect Dis* (2021).
- 423 12. Wang, Z., *et al.* Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Sci Transl Med* **13**(2021).
- 424 13. Iwasaki, A. Exploiting Mucosal Immunity for Antiviral Vaccines. *Annu Rev Immunol* **34**, 575-608  
425 (2016).
- 426 14. Russell, M.W. & Mestecky, J. Mucosal immunity: The missing link in comprehending SARS-CoV-2  
427 infection and transmission. *Front Immunol* **13**, 957107 (2022).
- 428 15. Cervia, C., *et al.* Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild  
429 versus severe COVID-19. *J Allergy Clin Immunol* **147**, 545-557.e549 (2021).
- 430 16. Smith, N., *et al.* Distinct systemic and mucosal immune responses during acute SARS-CoV-2  
431 infection. *Nature Immunology* **22**, 1428-1439 (2021).
- 432 17. Fröberg, J., *et al.* SARS-CoV-2 mucosal antibody development and persistence and their relation  
433 to viral load and COVID-19 symptoms. *Nature Communications* **12**, 5621 (2021).
- 434 18. Isho, B., *et al.* Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens  
435 in COVID-19 patients. *Sci Immunol* **5**(2020).
- 436 19. Liew, F., *et al.* Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced  
437 by subsequent vaccination. *medRxiv*, 2022.2009.2009.22279759 (2022).
- 438 20. Pouwels, K.B., *et al.* Effect of Delta variant on viral burden and vaccine effectiveness against new  
439 SARS-CoV-2 infections in the UK. *Nature Medicine* **27**, 2127-2135 (2021).
- 440 21. Singanayagam, A., *et al.* Community transmission and viral load kinetics of the SARS-CoV-2 delta  
441 (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective,  
442 longitudinal, cohort study. *Lancet Infect Dis* (2021).

- 443 22. Puhach, O., *et al.* Infectious viral load in unvaccinated and vaccinated individuals infected with  
444 ancestral, Delta or Omicron SARS-CoV-2. *Nat Med* (2022).
- 445 23. Woodbridge, Y., Amit, S., Huppert, A. & Kopelman, N.M. Viral load dynamics of SARS-CoV-2 Delta  
446 and Omicron variants following multiple vaccine doses and previous infection. *Nature*  
447 *Communications* **13**, 6706 (2022).
- 448 24. Ketas, T.J., *et al.* Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva.  
449 *Pathog Immun* **6**, 116-134 (2021).
- 450 25. Sheikh-Mohamed, S., *et al.* Systemic and mucosal IgA responses are variably induced in response  
451 to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent  
452 infection. *Mucosal Immunology* (2022).
- 453 26. Sano, K., *et al.* SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected  
454 individuals. *Nature Communications* **13**, 5135 (2022).
- 455 27. Collier, A.Y., *et al.* Characterization of immune responses in fully vaccinated individuals after  
456 breakthrough infection with the SARS-CoV-2 delta variant. *Sci Transl Med* **14**, eabn6150 (2022).
- 457 28. Planas, D., *et al.* Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2  
458 vaccinated individuals, with or without omicron breakthrough infection. *Med (N Y)* (2022).
- 459 29. Thwaites, R.S., *et al.* Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human  
460 Respiratory Mucosa and Laboratory Processing of Samples. *J Vis Exp* (2018).
- 461 30. Malato, J., *et al.* Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants.  
462 *N Engl J Med* (2022).
- 463 31. Butler, S.E., *et al.* Distinct Features and Functions of Systemic and Mucosal Humoral Immunity  
464 Among SARS-CoV-2 Convalescent Individuals. *Front Immunol* **11**, 618685 (2020).
- 465 32. Gonçalves, J., *et al.* Secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred  
466 to the breastmilk upon mRNA vaccination. *Cell Rep Med* **2**, 100468 (2021).
- 467 33. Ogata, A.F., *et al.* Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)  
468 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. *Clin Infect Dis* **74**, 715-  
469 718 (2022).
- 470 34. Su, F., Patel, G.B., Hu, S. & Chen, W. Induction of mucosal immunity through systemic  
471 immunization: Phantom or reality? *Hum Vaccin Immunother* **12**, 1070-1079 (2016).
- 472 35. Wright, P.F., *et al.* Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2  
473 Infection. *J Infect Dis* (2022).
- 474 36. Havervall, S., *et al.* Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection. *N*  
475 *Engl J Med* **387**, 1333-1336 (2022).
- 476 37. Meyts, I., *et al.* Coronavirus disease 2019 in patients with inborn errors of immunity: An  
477 international study. *J Allergy Clin Immunol* **147**, 520-531 (2021).
- 478 38. Port, J.R., *et al.* Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but  
479 increases competitiveness of Omicron in hamsters. *bioRxiv*, 2022.2007.2029.502072 (2022).
- 480 39. Lapuente, D., *et al.* Protective mucosal immunity against SARS-CoV-2 after heterologous systemic  
481 prime-mucosal boost immunization. *Nature Communications* **12**, 6871 (2021).
- 482 40. Mao, T., *et al.* Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against  
483 sarbecoviruses. *Science* **378**, eabo2523 (2022).

<b>Table 1: Participants characteristics</b>						
<b>Group</b>	<b>Negative</b>	<b>Vaccinated (2 doses)</b>	<b>Vaccinated (3 doses)</b>	<b>Convalescent</b>	<b>Hybrid Immunity (1 or 2 doses)</b>	<b>Hybrid Immunity (3 doses)</b>
<b>Group description</b>	Non-vaccinated, never tested positive, NP negative	Never tested positive, anti-NP negative, anti-S positive	Never tested positive	Non-vaccinated, tested positive	Infection after 1 or 2 doses of vaccine	Infection after 3 doses of vaccine
<b>Number of patients</b>	11	29	25	21	31	26
<b>Age: Median (range)</b>	28.5 (24-46)	33 (24-59)	37.5 (24 -76)	32 (23-64)	39 (25-59)	37.5 (23-55)
<b>Sex: Females (%)</b>	8 (72.7 %)	20 (69 %)	13 (52 %)	16 (76.2 %)	16 (51.6%)	15 (57.7 %)
<b>No of participants with &gt;1 infection</b>	na	na	na	2	8	3
<b>Days since last immune response, days, median (IQR)</b>	na	176 (163 - 210)	70 (50 - 123)	68 (38.25 - 364.75)	44 (29.5 - 54)	47.5 (38.25 - 56.25)
<b>Nr. of subjects with unknown date of infection</b>	na	na	na	3	-	-

485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500

501 **Figures**




502

503 **Figure 1. Correlation of SARS-CoV-2 IgA and IgG antibody responses in NLF and serum.** A,B. Correlation  
504 between anti-triS serum and NLF IgA (A) and IgG (B) antibody titers ( $\log_{10}$  ng/ml) of samples collected from  
505 convalescent, vaccinated and subjects with hybrid immunity. NLF triS IgA titers normalized to the levels  
506 of total IgA from the same sample. Pearson correlation coefficient and p values are shown.


507

508



509

510 **Figure 2. Mucosal and serum antibody responses in subjects with previous infection compared to vaccinated only.** A, B. Anti-triS IgA ( $\log_{10}$  ng/ml)  
 511 measured in NLF (A) and serum (B) of vaccinated with 2 or 3 doses, or convalescent. (C) Anti-triS s-IgA ( $\log_{10}$  AU/ml) antibody titers in NLF of  
 512 vaccinated with 2 or 3 doses, or convalescent. D,E. Anti-triS IgG ( $\log_{10}$  ng/ml) measured in NLF (D) and serum (E) of vaccinated with 2 or 3 doses,  
 513 or convalescent. One-way ANOVA with Tukey test was used to determine differences of means, p values are shown above brackets. The mean +  
 514 3SD of 11 negative samples was used to set a cut-off for anti-triS IgA, s-IgA and IgG in NLF. The mean + 3SD of 56 pre-pandemic serum samples  
 515 was used to set a cut-off for anti-triS IgA in serum samples. The mean + 3SD of 48 pre-pandemic serum samples was used to set a cut-off for anti-  
 516 triS IgG in serum samples.




517

518 **Figure 3. Mucosal and serum antibody responses in convalescent compared to subjects with hybrid immunity.** A, B. Anti-triS IgA (log<sub>10</sub> ng/ml)  
 519 measured in NLF (A) and serum (B) of convalescent or subjects with hybrid immunity. (C) Anti-triS s-IgA (log<sub>10</sub> AU/ml) antibody titers in NLF of  
 520 convalescent or subjects with hybrid immunity. D,E. Anti-triS IgG measured in NLF (D) and serum (E) of convalescent or subjects with hybrid  
 521 immunity. One-way ANOVA with Tukey test was used to determine differences of means, p values are shown above brackets. The mean + 3SD of  
 522 11 negative samples was used to set a cut-off for anti-triS IgA, s-IgA and IgG in NLF. The mean + 3SD of 56 pre-pandemic serum samples was used  
 523 to set a cut-off for anti-triS IgA in serum samples. The mean + 3SD of 48 pre-pandemic serum samples was used to set a cut-off for anti-triS IgG in  
 524 serum samples.




**A**

NLF Neutralization Ancestral




NLF s-IgA




**B**

NLF Neutralization Omicron BA.5



NLF s-IgA



525

526 **Figure 4. Neutralizing antibody responses in the nasal mucosae of vaccinated and subjects with hybrid**  
527 **immunity.** (A) Each dot represents the neutralizing titer (FRNT<sub>50</sub>) of an individual NLF sample against SARS-  
528 CoV-2 ancestral (A) and Omicron BA.5 variant (B). One-way ANOVA with Tukey test was used to determine  
529 differences of means, p values are shown above brackets. Anti-triS s-IgA and IgG titers in NLF from the  
530 same subjects were correlated with FRNT<sub>50</sub> neutralizing titers against SARS-CoV-2 ancestral (A) and  
531 Omicron BA.5 variant (B). Pearson correlation coefficient and p values are shown.

532

533 **Supplementary material**

534

<b>Table S1</b>	<b>Participants characteristics (extended)</b>					
<b>Group</b>	<b>Negative</b>	<b>Vaccinated (2 doses)</b>	<b>Vaccinated (3 doses)</b>	<b>Convalescent</b>	<b>Hybrid Immunity (1 or 2 doses)</b>	<b>Hybrid Immunity (3 doses)</b>
Interval vaccination to infection, days, mean (IQR)	na	na	na	na	170 (144.5 -197)	64 (35 – 111)
Interval vaccination to sampling, days, median (IQR)	na	176 (163 – 210)	70 (50- 123)	na	222 (195-248.5)	108 (82 – 158)
Interval infection to sampling, days, median (IQR)	na	na	na	68 (38.25 - 364.75)	44 (29.5 - 54)	47.5 (38.25 - 56.25)
Date of infection is not known (nr of patients)	na	na	na	3	-	-
Latest Infecting variant						
Pre-VOC	na	na	na	1	-	-
Delta	na	na	na	3	13	2
Omicron (BA.1/BA.2)	na	na	na	8	9	20
Unknown variant	na	na	na	9	9	4
Vaccine						
BNT162b2	na	14	16	na	14	15
mRNA-1273	na	15	4	na	15	5
AZD1222 (2 doses) + BNT162b2 (Booster)	na		2	na		1
mRNA-1273 (2 doses) + BNT162b2 (booster)	na		3	na		2
BNT162b2 (2 doses) + mRNA-1273 (booster)	na			na		1
Vaccine unknown	na			na	2	2


535

536

537


538

539




540

541 **Figure S1. Validation of serum and NLF samples.** The levels of SARS-CoV-2 anti-RBD (A) and NP (B) were  
542 measured in serum using Roche Elecsys anti-SARS-CoV-2 S (A) and SARS-CoV-2 (B) total Ig assay. (C) Levels  
543 of total IgA in the NLF samples. One-way ANOVA with Tukey test was used to determine differences of  
544 means, p values are shown above brackets.



545

546 **Figure S2. SARS-CoV-2 anti-Spike s-IgA and IgA responses in nasal mucosa.** Correlation between anti-triS  
547 IgA and s-IgA antibody titers in NLF collected from convalescent, vaccinated and subjects with hybrid  
548 immunity. Pearson correlation coefficient and p values are shown.



549

550 **Figure S3. SARS-CoV-2 anti-nucleoprotein responses in individuals with previous infection.** (A)  
551 Correlation between anti-triS and anti-NP s-IgA titers in NLF samples of convalescent or individuals with  
552 hybrid immunity. Pearson correlation coefficient and p values are shown. (B) Levels of anti-NP s-IgA titers  
553 of convalescent or individuals with hybrid immunity. One-way ANOVA with Tukey test was used to  
554 determine differences of means, p values are shown above brackets.